AstraZeneca's (AZN LN) Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)

The drug sits in the complement inhibitor class that Alexion established in rare neuromuscular disease, and AstraZeneca's rare disease franchise has a track record of converting positive opinions into label without late-stage reversal. The read-through that matters is franchise durability: an additional approved product in generalised myasthenia gravis extends the company's position against the FcRn class that has been taking share in this indication, and the competitive dynamic between complement inhibition and FcRn blockade has been the defining feature of the gMG market. Equity reaction to CHMP opinions of this kind has tended to be modest, since the step is well telegraphed and consensus usually models approval; the bigger moves have historically come from initial launch data and payer negotiations across member states, where reimbursement sequencing varies widely. Worth noting is the follow-on calendar: formal approval, then country-level pricing and any label breadth relative to the pivotal trial population.